Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has begun treating its second cohort of patients as part of the first-in-human study for the company’s DurAVR™ transcatheter heart valve system.
Anteris is a structural heart company focused on developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.
The company’s DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of more active aortic stenosis patients by delivering durability designed to last the remainder of a patient’s lifetime.
The benefits of Anteris’ patented ADAPT® tissue technology, paired with the unique design of its DurAVR™ 3D single-piece aortic heart valve, are aimed at providing a much-needed solution to the challenges facing doctors today.
The news relating to its second cohort of patients comes just a day after the company announced it was strengthening its Australian Medical Advisory Board with the appointment of Associate Professor Dion Stub MBBS, PhD, FRACP of the Alfred Hospital and Monash University.
Associate Professor Stub has significant TAVI experience and specialises in structural heart procedures.
Read: Anteris Technologies enhances Australian Medical Advisory Board